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other inputs came from published literature. RESULTS: When compared to the
average patient population, initiation of ATV/r- or LPV/r-based treatments (with
CD4 cell 200 cells/m3 at baseline) in treatment-naïve patients were cost-effec-
tive strategies resulting in more life-years and quality-adjusted life years (QALYs)
gained, at lower overall costs. Initiation of ATV/r treatment provided greater effec-
tiveness (additional 1.69 life-years and 1.77 QALYs) and lower costs (€162,460 vs.
€177,038; 2010 values) compared with LPV/r (5% discounting for costs and effects).
CONCLUSIONS: Initiating treatment with ARV agents when CD4 cell 200
cells/m3 was predicted to lower overall treatment costs, lead to increased survival
and fewer ADEs. Similarly, initiating treatment with ATV/r rather than LPV/r rep-
resented a cost-effective strategy in treatment naïve patients with HIV-1 infection.
Probabilistic sensitivity analyses were performed and confirmed the robustness of
the base-case findings.
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OBJECTIVES: Candidemia or invasive candidiasis is a nosocomial infection associ-
ated with considerable mortality and with substantial economic impact due to its
long hospital length of stay. The role of appropriate initial antifungal agent is
crucial for improved outcomes and reduced hospital costs. This study evaluated
the cost-effectiveness of anidulafungin as a new echinocandin, by comparing
anidulafungin with fluconazole in the treatment of candidemia or invasive
candidiasis.METHODS:A decision analyticmodel was developed, from the Korean
health care systemperspective, to examine the cost-effectiveness of anidulafungin
compared with fluconazole. Efficacy data on treatment success, renal toxicity, and
survival were obtained from the clinical trial studywhich compared anidulafungin
with fluconazole (Reboli, 2007). Drug cost and othermedical cost were derived from
a cost of illness study of candidemia in Korea. Average cost-effectiveness and
incremental cost-effectiveness of each drug per survival patient were calculated.
RESULTS: The overall survival rate was higher for patients treated with anidula-
fungin than with fluconazole (77.17% vs. 68.64%). The total costs were 6,929,620
KRW for anidulafungin and 6,629,357KRW for fluconazole. However, because of the
better clinical efficacy, the average cost-effectiveness per survival patient was
lower for the anidulafungin treatment than fluconazole treatment (8,980,222 KRW
vs. 9,657,582 KRW). The incremental cost-effectiveness of anidulafungin compared
with fluconazole was estimated to be 3,532,684 KRW. CONCLUSIONS: Anidulafun-
gin indicated better clinical efficacy in managing candidemia or invasive candidi-
asis. Although there is an increase in drug costs, treating candidemia or invasive
candidiasis with anidulafungin is a cost-effectiveness strategy. This study shows
that anidulafungin as first-line therapy can be cost-effectiveness alternative to
fluconazole in candidemia or invasive candidiasis treatment.
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OBJECTIVES: Ventilator-associated pneumonia (VAP) is an infection acquired in
hospitals with important clinical and economic implications, which raise morbid-
ity and costswithinNational Health Systems. The aim of this studywas to evaluate
the cost-effectiveness of linezolid versus vancomycin for the empiric treatment of
mechanical ventilator associated pneumonia caused by Methicillin-Resistant
Staphylococcus aureus (VAP-MRSA) from the payer’s perspective in Colombia.
METHODS: A validated decision-tree model was developed to assess the cost-
effectiveness of linezolid (600mg/12hrs) against vancomycin (1gr/12hrs) for a co-
hort of adult patients with VAP-MRSA. The model simulated costs and effective-
ness within a time horizon of 90 days. Outcome measure was defined as life-years
gained (LYG). Clinical efficacy and transition probabilities were collected through a
literature review of published clinical trials and validated by a Colombian Delphi
Panel. The Panel also estimated directmedical resource utilization associated with
VAP-MRSA treatment (drugs, hospitalization, and costs associated with adverse
events: thrombocytopenia or renal failure). Unit costs from Colombian price man-
ual (SOAT) was used; acquisition costs were retrieved from the Colombian official
report (SISMED) and by the Law3470/2011. Incremental cost-effectiveness ratio and
sensitivity analyses for key variableswere performed for testingmodel robustness.
Results were expressed in 2011 US$. RESULTS: Patients treated with linezolid
achieved the highest LYG compared to vancomycin (5.63 vs. 3.40), with a shorter
intensive care unit (ICU) length of stay (12.2 vs. 16.2 days respectively). Overall
treatment costs were lower for linezolid versus vancomycin (US$3356.29 vs.
US$3566.42). Therefore linezolid demonstrated to be a cost-saving alternative,
compared to vancomycin. Likewise, the probability of clinical recovery, death,
switch of antibiotic therapy and daily cost in ICU were the most impactful factors
that affected health net profit without changing above conclusions.
CONCLUSIONS: Linezolid generates savings to the Colombian health system and it
is a cost-saving therapy for treating VAP-MRSA adult patients.
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OBJECTIVES: In 2009, theH1N1 influenza epidemic in theUnited States caused over
19,000 deaths. This study aims to conduct an economic evaluation of the twomost
commonly recommended treatment choices for the H1N1 flu, oseltamivir and
zanamivir. METHODS: A cost effectiveness analysis was performed by evaluating
randomized clinical trials (RCTs) and other published literature for oseltamivir and
zanamivir. Direct medical costs included drug costs, cost of hospitalization, cost
associated with complications and adverse drug events. Effectiveness was as-
sessed using efficacy data from RCTs. All costs were adjusted to 2011 USD using
consumer price index. The primary outcome measures were the duration and
severity of illness in infected patients. A decision tree analysis model was devel-
oped using TreeAge Pro 2009 from aUS third party perspective. Oneway sensitivity
analysis using total cost was conducted to evaluate the robustness of results.
RESULTS: Efficacy of oseltamivir and zanamivir was found to be 69% and 81%,
respectively. Total cost for treating H1N1 patient was higher for oseltamivir ($1878)
compared to zanamivir ($1099). The expected cost of treatment per unit change
was higher for osletamivir ($27.2) compared to zanamivir ($13.6). ICERwas found to
be $64.91 per unit change. Results of one way sensitivity analysis were robust with
results of the decision tree model. CONCLUSIONS: This study provides some pre-
liminary conclusion that zanamivir was more cost effective as compared to osel-
tamivir for treatment of H1N1flu, fromUS third party perspective. Further research
with prospective data may help providers make informed decisions, if such an
epidemic happens again.
PIN41
COST-EFFECTIVENESS OF VACCINATION AGAINST YELLOW FEVER IN GHANA
Ankrah D
Korle-Bu Teaching Hospital, Accra, Ghana
OBJECTIVES: Yellow fever is a haemorrhagic disease caused by arbovirus from the
flavivirus genus. It is a disease that has no cure currently and up to 50% of those
affected may die. According to the reports about 20% of the population may be
affected during a typical outbreak. The only way to prevent the disease is through
vaccination. Although vaccine efficacy is over 95%, neurotropic, viscerotropic and
hypersentivity adverse events following immunization are associated with vacci-
nation. The objective was to assess the cost-effectiveness of vaccination (against
yellow fever) in a country endemic to the yellow fever disease.METHODS: A deci-
sion analytic model using decision tree was employed in this research. The deci-
sion as to whether or not the yellow fever vaccination (among healthy people 10
years or older) should be givenwas characterized. The probability of adverse events
following immunization (AEFIs) and the probability of treatment among vaccinees
were calculated. Among non vaccinees, the probability of an infection with the
yellow fever was calculated. Thesewere done using estimates predominantly from
the literature. Costswere assigned to the various event pathways using the societal
perspective and expected costs of the outcomes were then calculated. RESULTS:
The expected cost for vaccination was less than $1.00 and the expected cost for
non-vaccination was $30.50. Vaccination against yellow fever had a higher effect
than non-vaccination. CONCLUSIONS: Vaccination against yellow fever among
Ghanaians, ten years or olderwas cost-effective. People should be encouraged to go
for the vaccination because the disease is endemic in the region.
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OBJECTIVES: Telaprevir is a new direct acting antiviral for the treatment of G1
hepatitis C virus (HCV) infection. A post-hoc analysis was conducted to evaluate
the cost-effectiveness of patients according to IL-28B subgroups in both treatment
naïve and previously treated G1 chronic HCV patients. Cost-effectiveness is con-
sidered in terms of incremental cost per quality-adjusted life-year (QALY) gained
from the perspective of the NHS in England and Wales. METHODS: Two Markov-
models were developed to evaluate treatments studied in TVR phase III clinical
trials: TVR response-guided therapy of 12 weeks of TVR with PR [24 weeks PR for
patients achieving an extended rapid viral response (eRVR), 48 weeks of PR for
patients not achieving an eRVR] for treatment-naïve patients; 12 weeks of TVR in
combination with 48 weeks of PR therapy for treatment-experienced patients. IL-
28B datawas available for 140 and 161 T12/PR and PBO/PR patients, equating to 39%
and 45% of all T12/PR and PBO/PR patients in ADVANCE, respectively. IL-28B geno-
type data was available for 212 and 105 T12/PR and PBO/PR patients, equating to
80% of all patients in both treatment arms in REALIZE. Among T12/PR patients the
CC, CT and TT distribution was 19%, 63% and 17% respectively; among PBO/PR
patients the distribution was 16%, 55% and 29% respectively. RESULTS: TVR based
therapy was cost-effective when compared to PBO/PR regimen in both treatment-
naïve and experienced patients regardless of IL-28B subtypes (CC, CT, and TT).
CONCLUSIONS: The introduction of telaprevir to current standard of care for HCV
genotype 1 patients is clinicallymore efficacious than PR alone and cost-effective at
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